Polycystic Kidney Disease Clinical Trials

Find Polycystic Kidney Disease Clinical Trials Near You

Effects of Exogenous Ketosis on Proteinuria and Renal Function in Patients with Chronic Kidney Disease and Patients with Polycystic Kidney Disease

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

A randomized, placebo-controlled, double-blinded crossover study will be conducted. Fourteen patients with polycystic kidney disease (PKD) and 29 patients with proteinuric kidney disease will receive ketone bodies (Ketone-IQ) and placebo in a randomized order. Each treatment period is four weeks. There will be a wash-out period of two weeks in between treatment periods. Effect variables will be measured in the last day of each treatment period.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ Study A (patients with CKD):

• ACR \> 200 mg/g \<3000 mg/g

• eGFR \>30 ml/min/1,73m2

• Treatment with Renin-Angiotension System (RAS) blockers and SGLT-2 inhibitors for a minimum of 4 weeks prior to inclusion

• Safe contraception if women in childbearing age

⁃ Study B (patients with PKD):

• Prior diagnose with PKD

• eGFR \>30 ml/min/1,73m2

• Treatment with Renin-Angiotension System (RAS) blockers for a minimum of 4 weeks prior to inclusion

• Safe contraception if women in childbearing age

Locations
Other Locations
Denmark
University Clinic in Nephrology and Hypertension, Gødstrup Region Hospital
RECRUITING
Herning
Contact Information
Primary
Trine Z Lyksholm, MD
trizur@rm.dk
78432534
Time Frame
Start Date: 2024-09-11
Estimated Completion Date: 2025-12
Participants
Target number of participants: 43
Treatments
Other: Ketone diol (Ketone-IQ), then Placebo drink
For four weeks each subject will receive Ketone Diol, R-1,3-butanediol, administered as a drink (Ketone-IQ) twice a day, then crossed over to receive a taste and volume matched placebo drink for four weeks.~Each individual will receive 400mg/kg before bedtime in addition to 200mg/kg with a minimum of 6 hours in between throughout the treatment period.
Other: Placebo drink, then Ketone diol (Ketone-IQ)
For four weeks each subject will receive a placebo drink twice a day, then crossed over to receive Ketone Diol, R-1,3-butanediol, administered as a drink (Ketone-IQ) twice a day for four weeks.~Each individual will receive 400mg/kg before bedtime in addition to 200mg/kg with a minimum of 6 hours in between throughout the treatment period.
Related Therapeutic Areas
Polycystic Kidney Disease
Sponsors
Leads: Gødstrup Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

Enrollment Status: Recruiting
Publish Date: September 12, 2025
Intervention Type: Drug
Study Phase: Phase 2

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Enrollment Status: Recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Phase: Phase 2

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life

Enrollment Status: Recruiting
Publish Date: February 25, 2026
Intervention Type: Drug
Study Phase: Phase 3
View All